Charles River Laboratories EBITDA 2010-2024 | CRL

Charles River Laboratories EBITDA for the quarter ending December 31, 2024 was $0.149B, a 29.99% decline year-over-year.

  • Charles River Laboratories 2024 EBITDA was 0.804B, a 13.67% decline from 2023.
  • Charles River Laboratories 2023 EBITDA was 0.931B, a 2.46% decline from 2022.
  • Charles River Laboratories 2022 EBITDA was 0.955B, a 11.63% increase from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Charles River Laboratories EBITDA 2010-2024 | CRL

  • Charles River Laboratories 2024 EBITDA was 0.804B, a 13.67% decline from 2023.
  • Charles River Laboratories 2023 EBITDA was 0.931B, a 2.46% decline from 2022.
  • Charles River Laboratories 2022 EBITDA was 0.955B, a 11.63% increase from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$148.1B
Elevance Health (ELV)$90.8B
CVS Health (CVS)$83.7B
Cencora (COR)$47.6B
DiDi Global (DIDIY)$23.1B
Natera (NTRA)$22.8B
ICON (ICLR)$15.8B
Doximity (DOCS)$14.3B
BioMerieux (BMXMF)$14.1B
Revvity (RVTY)$14B
Viatris (VTRS)$13B
Solventum (SOLV)$12.8B
Avantor (AVTR)$12B
CochLear (CHEOY)$11.5B
Medpace Holdings (MEDP)$10.5B
HealthEquity (HQY)$9.9B
EUROFINS SCIENT (ERFSF)$9.5B
Sonic Healthcare (SKHHY)$8.8B
Amplifon S.p.A (AMFPF)$6.2B
Bausch + Lomb (BLCO)$5.7B
Organon (OGN)$3.9B
Sotera Health (SHC)$3.9B
BrightSpring Health Services (BTSG)$3.6B
Surgery Partners (SGRY)$3.3B
GeneDx Holdings (WGS)$3.1B
Concentras Parent (CON)$3B
Alignment Healthcare (ALHC)$2.7B
Teladoc Health (TDOC)$2.4B
Ardent Health Partners (ARDT)$2.1B
Progyny (PGNY)$2B